688098 Shanghai Shen Lian Biomedical Corporation
- 5.59
- +0.06+1.08%
Shanghai Shen Lian Biomedical Corporation News
Shenlian Biology (688098.SH): At present, it has accumulated synthetic biotechnology based on yeast strains, etc.
Gelonghui, May 8, 丨 Shenlian Biology (688098.SH) said on the interactive platform that the company has now accumulated synthetic biotechnology based on yeast strains, etc., and related platforms are in the process of development and construction, and no related products have yet been produced.
Express News | Shenlian Biology: Swine Fever Genetically Engineered Subunit Vaccine Approved for New Veterinary Drug Registration
Shenlian Biotech (688098.SH): Swine Fever Vaccine Approved for New Veterinary Drug Registration
On May 5, Ge Longhui Biotech (688098.SH) issued a notice to approve the company's swine fever genetically-engineered subunit vaccine (CHO-133D) as a new veterinary drug and issued a “New Veterinary Drug Registration Certificate” after review by the Ministry of Agriculture and Rural Affairs of China in accordance with the “Veterinary Drug Administration Regulations” and the “Veterinary Drug Registration Measures”.
Shenlian Biotech (688098.SH): Net loss of 2.09 million yuan in the first quarter
Gelonghui, April 26 | Shenlian Biotech (688098.SH) released its first quarter report. Operating revenue was 880.58 million yuan, up 7.58% year on year, with a net loss of 2.209 million yuan, after deducting non-net loss of 2.889 million yuan, and basic earnings per share of -0.01 yuan.
Express News | Shenlian Biotech: Bovine Tuberous Dermatosis Inactivated Vaccine Obtains Veterinary Drug Product Approval Number Approval
Shenlian Biotech (688098.SH): 2023 net profit of 31,518,700 yuan decreased by 48.42% year-on-year
Gelonghui, Feb. 28, 丨 Shenlian Biotech (688098.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 301.4871 million yuan, down 8.25% from the previous year; net profit attributable to owners of the parent company was 31.518,700 yuan, down 48.42% from the previous year.
Express News | Today, 76 A-share stocks were traded in bulk. Bohai Leasing, China Eastern Airlines, and Kweichow Moutai ranked in the top three in terms of turnover
[BT Financial Report Instantaneous Analysis] Shenlian Biotech's 2023 Quarterly Report: Performance and Market-based Sales Process in the Face of Challenges
Shenlian Biomedical (Shanghai) Co., Ltd. (stock code: 688098) is a high-tech enterprise focusing on R&D, production and sales of veterinary biological products. The company's main business is veterinary preventive biological products and veterinary diagnostic products, and has two major veterinary drug GMP production bases in Shanghai and Lanzhou. The products already marketed by Shenlian Biotech include pig foot-and-mouth disease vaccine, cattle and sheep foot-and-mouth disease vaccine, swine ring vaccine, foot-and-mouth disease and African swine fever diagnostic reagents. Among them, pig foot-and-mouth disease type O and type A bivalent inactivated vaccines are important products of the company. In terms of assets and liabilities, Shenlian Biotech's 2023 three-quarter report shows that the public
Shanghai Hongchao, a shareholder of Shenlian Biotech (688098.SH), and his co-actors reduced their holdings of the company by a total of 2.35%
Shenlian Biotech (688098.SH) announced that Shanghai Hongchao Industrial Investment Co., Ltd. (“Shanghai Hongchao”), a shareholder of the company...
Shen Lian Biomedical Obtains Production License, GMP Certificate
Shanghai Shen Lian Biomedical (SHA:688098) obtained a drug production license after passing the good manufacturing practice inspection of the Animal Husbandry and Veterinary Bureau of China's Gansu Pr
Shenlian Biotech (688098.SH): Obtained the “Veterinary Drug GMP Certificate” and the “Veterinary Drug Production License”
Gelonghui November 20丨Shenlian Biotech (688098.SH) announced that the Lanzhou branch recently passed the veterinary drug GMP inspection and obtained the “Veterinary Drug GMP Certificate” and “Veterinary Drug Production License” issued by the Gansu Provincial Bureau of Animal Husbandry and Veterinary Medicine. The company's cell suspension culture virus inactivated vaccine (including cell suspension culture virus subunit vaccine) production line that has passed the inspection can be used to produce products such as bovine nodular skin disease inactivated vaccine, porcine seneca virus disease inactivated vaccine, porcine pseudorabies virus gene deletion inactivated vaccine, porcine infectious gastroenteritis, swine epidemic diarrhea, and porcine delta coronavirus disease triple inactivated vaccine.
Shenlian Biotech (688098.SH) reported the first three quarter results, net profit of 37.1243 million yuan, a year-on-year decrease of 48.70%
Shenlian Biotech (688098.SH) released its report for the first three quarters of 2023, with revenue of 239 million yuan, the same...
Shen Lian Biomedical Forms Tie-up to Develop African Swine Fever Vaccine
Shanghai Shen Lian Biomedical (SHA:688098) partnered with the Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences to research and develop a vaccine against African s
Shen Lian Biotech (688098.SH) released first-half results, with net profit of 9.932 million yuan, a year-on-year decrease of 57.35%
Shen Lian Biotech (688098.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Shen Lian Biomedical Passes Regulatory Inspection
Shanghai Shen Lian Biomedical (SHA:688098) passed the good clinical practice inspection of China's Ministry of Agriculture and Rural Affairs. The regulator inspected the veterinary product manufacture
Shenlian Biology (688098.SH) passed the Ministry of Agriculture and Rural Affairs veterinary drug GCP supervision and inspection
According to the Zhitong Finance App, Shen Lian Biology (688098.SH) announced that the company recently passed the supervision and inspection of the Veterinary Drug Clinical Trial Quality Management Code (GCP) of the Bureau of Animal Husbandry and Veterinary Medicine of the Ministry of Agriculture and Rural Affairs. According to the announcement, a total of 2 supervision and inspection projects have passed the Veterinary Drug Clinical Trial Quality Management Code (GCP) of the Bureau of Animal Husbandry and Veterinary Medicine of the Ministry of Agriculture and Rural Affairs, which indicates that the company is qualified to carry out clinical trials on the safety and efficacy of veterinary biological products in pigs, laying a solid foundation for the rapid advancement of the company's new product research and development projects; at the same time, it marks that the company's veterinary drug standardization innovation and evaluation capabilities have reached a new level.
Shanghai Hongchao, a shareholder of Shenlian Biotech (688098.SH), and its co-actors reduced their holdings of the company by 1.5% by a total of 1.5%
According to the Zhitong Finance App, Shen Lian Biology (688098.SH) announced that on August 2, 2023, the company received a “Notice on the Progress of Implementation of the Share Holding Reduction Plan” from shareholder Shanghai Hongchao and its co-actor Shanghai Fenghong. From May 24 to August 2, 2023, Shanghai Hongchao and its co-actor Shanghai Fenghong reduced their holdings by a total of 6.154,900 shares, accounting for 1.5% of the company's total share capital. The amount of holdings reduced in this holdings reduction plan has been reduced by more than half, and the implementation of the holdings reduction plan has not yet been completed.
Shanghai Fenghong, a shareholder of Shenlian Biotech (688098.SH), and his co-actors reduced their holdings by 1.04% to less than 5% of total shares and apologized for violating credit disclosure regulations by reducing their holdings
According to the Zhitong Finance App, Shen Lian Biotech (688098.SH) announced that on July 6, 2023, the company received “Instructions on Changes in Shareholders' Equities and Apologies” and “Simplified Equity Change Report” issued by the shareholder Shanghai Hongchao Industrial Investment Co., Ltd. (hereinafter referred to as “Shanghai Hongchao”) and its co-actor Shanghai Fenghong Technology Development Partnership (Limited Partnership) (hereinafter referred to as “Shanghai Fenghong”), as of July 5, 2023, Shanghai Hongchao and its co-actor, Shanghai Fenghong, reduced centralized bidding and bulk trading methods 4.255,800 shares Shares (change ratio is 1.0
Shen Lian Biology (688098.SH): Shanghai Hongchao and its co-actor Shanghai Fenghong's shareholding ratio decreased from 5.19% to 4.15%
On July 6, 2023, GLONGHUI | Shenlian Biology (688098.SH) announced that on July 6, 2023, the company received “Instructions on Shareholders' Equity Changes and Apologies” and “Simplified Equity Change Report” from shareholder Shanghai Hongchao and his co-actor Shanghai Fenghong. As of July 5, 2023, due to centralized bidding and bulk trading methods, the shareholding ratio of Shanghai Hongchao and its co-actor Shanghai Fenghong had decreased from 5.19% to 4.15%, and the equity change ratio was over 1%. From May 25, 2023 to July 5, 2023, Shanghai Hongchao and his co-actor Shanghai
The registration date for Shenlian Biotech (688098.SH) to distribute shares of 0.08 yuan per share in 2022 is June 12
According to the Zhitong Finance App, Shenlian Biotech (688098.SH) announced that the company will implement the 2022 annual equity distribution, with a cash dividend of 0.08 yuan (tax included) per share. The equity registration date is June 12.
Analysis
Price Target
No Data
